U.S. markets closed

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.8100-0.0700 (-3.72%)
At close: 04:00PM EDT
1.7800 -0.03 (-1.66%)
After hours: 04:24PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.8800
Bid1.7800 x 1200
Ask1.8100 x 1000
Day's Range1.7850 - 1.9300
52 Week Range1.7850 - 10.4200
Avg. Volume1,003,079
Market Cap89.036M
Beta (5Y Monthly)2.08
PE Ratio (TTM)N/A
EPS (TTM)-2.6300
Earnings DateNov 01, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CCCC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • C4 Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/13/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    C4 Therapeutics Announces Chief Financial Officer Succession

    Kendra Adams Kendra Adams, Chief Financial Officer WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Kendra Adams as chief financial officer (CFO), effective September 18, 2023. She will succeed Lauren White, who will be

  • Insider Monkey

    12 Best High Risk Penny Stocks to Buy Now

    In this article, we will take a look at the 12 best high risk penny stocks to buy now. To see more such companies, go directly to 5 Best High Risk Penny Stocks to Buy Now. Investors are jubilant over Nvidia crushing analyst estimates in its latest quarterly report. Analysts are increasing their price targets […]

  • Zacks

    C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates

    C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 1.35% and 69.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?